Revvity, Inc. (RVTY)
Results announcedQ3 FY2026quarter ended 4 October 2026, announced 3 November 2026
Net income$62 millionup 33.5% on Q3 FY2025
From the company's results press release. The tables update when the 10-Q or 10-K is filed. Read the results · Read the release
Revvity supplies health science technologies, expertise and services covering workflows from discovery to development and from diagnosis to cure. The filing names its focus areas as translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. Headquarters are in Waltham, Massachusetts, products and services are marketed in more than 160 countries, and the company employed approximately 11,000 people at 28 December 2025, roughly 80 percent of them outside the United States, with about 4,000 covered by employment contracts influenced by labour unions and workers' councils. The financial year ends in late December. There are two segments, Life Sciences and Diagnostics.
Compare with another name What $10,000 in Revvity became Open in your desk ↗
Latest results
this quarterthe same quarter a year earlierHover a bar for its figure.
this yearthe year beforeHover a bar for its figure.
The years before, in words
Revvity (RVTY) reported revenue of $2.9 billion for fiscal 2025, the year ended 28 December 2025, up 3.7% on the year before. Net income was $241 million and diluted earnings per share $2.07. Revenue was $2.8 billion in fiscal 2024, $2.8 billion in fiscal 2023, $3.3 billion in fiscal 2022 and $3.8 billion in fiscal 2021. Net income in the same years was $270 million, $693 million, $569 million and $943 million. Over the twelve months to 5 July 2026, Revvity reported revenue of $2.9 billion and net income of $238 million. Revenue grew 1.4% a year, compounded, over the five years to fiscal 2025. Revvity declared $0.28 a share in dividends over the last four quarters and had 112 million shares outstanding at the latest filed count. At 5 July 2026 it carried $3.2 billion of debt and $1.0 billion of cash. At the close of 6 November 2026 the market cap of Revvity was $17.3 billion, 73.9 times its earnings over the last twelve months.Ratios
From the filings
ROE3.3%
ROCE3.4%
Operating margin12.3%
Net margin8.2%
FCF margin19.2%
Interest cover3.8x
Debt to equity0.45x
Cash conversion2.64x
Share count, last 12 months-4.1%
Sales CAGR, 3 years-4.8%
Profit CAGR, 3 years-24.9%
EPS, TTM$2.10
At the close of 6 November 2026
Price$155.16
Market cap$17.3 billion
Stock P/E73.9x
Price to book2.4x
EV / EBITDA25.3x
Dividend yield0.2%
Market cap / sales6.0x
52-week high$165.71
52-week low$82.26
Price, 1 year73.3%
Price CAGR, 3 years22.0%
Price CAGR, 5 years-1.7%
29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →
Worked from the filed figures; hover a name for the formula.
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the total debt Revvity, Inc. states in its own filing, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.RVTYgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.Quarterly results
| Q3 FY2021 † | Q4 FY2021 | Q1 FY2022 † | Q2 FY2022 † | Q3 FY2022 † | Q4 FY2022 † | Q1 FY2023 | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 * | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 861 | 1,028 | 963 | 896 | 712 | 741 | 675 | 709 | 671 | 696 | 650 | 692 | 684 | 729 | 665 | 720 | 699 | 772 | 711 | 730 |
| Cost of revenue | 338 | 615 | 368 | 344 | 305 | 305 | 293 | 307 | 298 | 312 | 295 | 306 | 299 | 317 | 289 | 328 | 324 | 350 | 323 | 313 |
| Gross profit | 523 | 644 | 595 | 552 | 407 | 436 | 381 | 402 | 373 | 383 | 355 | 386 | 385 | 412 | 376 | 393 | 375 | 422 | 388 | 417 |
| Gross margin | 61% | 63% | 62% | 62% | 57% | 59% | 57% | 57% | 56% | 55% | 55% | 56% | 56% | 57% | 56% | 55% | 54% | 55% | 55% | 57% |
| R&D | 49.4 | 80.3 | 57.5 | 56.0 | 53.5 | 54.5 | 56.7 | 57.3 | 53.0 | 49.6 | 50.4 | 48.1 | 49.1 | 49.2 | 53.6 | 53.3 | 50.8 | 58.2 | 57.9 | 49.0 |
| SG&A | 276 | 355 | 275 | 263 | 243 | 244 | 249 | 267 | 250 | 257 | 261 | 252 | 238 | 244 | 250 | 249 | 242 | 252 | 254 | 279 |
| Operating income | 196 | 300 | 262 | 232 | 111 | 137 | 76.1 | 78.1 | 69.2 | 77.2 | 44.1 | 85.7 | 98.2 | 119 | 72.2 | 90.8 | 81.9 | 112 | 75.9 | 89.3 |
| Operating margin | 23% | 29% | 27% | 26% | 16% | 19% | 11% | 11% | 10% | 11% | 7% | 12% | 14% | 16% | 11% | 13% | 12% | 14% | 11% | 12% |
| Interest expense | 43.5 | n/a | 28.4 | 27.1 | 25.9 | 22.5 | 22.7 | 26.0 | 25.5 | 24.6 | 24.4 | 24.7 | 24.4 | 22.8 | 23.0 | 22.9 | 22.8 | 23.5 | 24.7 | 23.0 |
| Pre-tax income | 135 | 300 | 225 | 206 | 82.1 | 138 | 29.4 | 71.6 | 50.6 | 31.4 | 34.5 | 86.7 | 100 | 94.6 | 52.4 | 68.7 | 55.7 | 91.6 | 50.0 | 63.5 |
| Tax rate | 20% | 41% | 18% | 22% | 15% | 30% | 16% | 18% | 36% | -103% | 17% | 16% | 7% | 7% | 20% | 20% | 15% | -5% | 18% | 16% |
| Net income | 128 | 190 | 177 | 179 | 85.3 | 128 | 569 | 35.6 | 9.5 | 78.6 | 26.0 | 55.4 | 94.4 | 94.6 | 42.2 | 53.9 | 46.7 | 98.4 | 40.7 | 51.8 |
| Net margin | 15% | 19% | 18% | 20% | 12% | 17% | 84% | 5% | 1% | 11% | 4% | 8% | 14% | 13% | 6% | 7% | 7% | 13% | 6% | 7% |
| Diluted EPS | $1.11 | $1.50 | $1.40 | $1.42 | $0.67 | $1.01 | $4.50 | $0.28 | $0.08 | $0.64 | $0.21 | $0.45 | $0.77 | $0.78 | $0.35 | $0.46 | $0.40 | $0.87 | $0.36 | $0.47 |
| Operating cash flow | 314 | 336 | 283 | 97.5 | 160 | 139 | 63.5 | -135 | -33.5 | 197 | 148 | 159 | 148 | 174 | 128 | 134 | 138 | 182 | 115 | 192 |
| Capital expenditure | 32.8 | 32.4 | 29.4 | 23.2 | 6.9 | 26.1 | 20.9 | 13.9 | 22.4 | 24.1 | 17.8 | 22.0 | 22.3 | 24.5 | 16.0 | 18.9 | 18.5 | 20.2 | 19.8 | 11.1 |
| Free cash flow | 281 | 303 | 254 | 74.3 | 153 | 113 | 42.5 | -149 | -55.8 | 172 | 130 | 137 | 126 | 150 | 112 | 115 | 120 | 162 | 95.5 | 181 |
| Buybacks | 0.1 | 0.1 | 55.6 | 0.5 | 0.1 | 24.5 | 61.7 | 212 | 111 | 4.9 | 10.8 | 19.6 | 154 | 185 | 154 | 294 | 205 | 168 | 86.5 | 16.0 |
| Dividends paid | 7.8 | 8.8 | 8.8 | 8.8 | 8.8 | 8.8 | 8.8 | 8.8 | 8.7 | 8.6 | 8.6 | 8.6 | 8.6 | 8.5 | 8.4 | 8.3 | 8.1 | 8.0 | 7.8 | 7.8 |
| Shares outstanding | 126m | 126m | 126m | 126m | 126m | 126m | 126m | 124m | 123m | 123m | 123m | 123m | 122m | 121m | 119m | 116m | 114m | 112m | 112m | 112m |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.Income statement (profit and loss)
Play it forward: change any box and its column follows; every box opens at the company's own record, shown under the row's name, and says when you set it outside every year in the table.
Read more
Each column runs from the last twelve months as filed to the year chosen in its heading, at a yearly rate. Sales growth starts at the company's own five-year rate and eases a third of the way each year toward the median of the 42 peers in Measuring and Control Equipment (9.4% a year), because a rate far from the rest rarely lasts. Before you open a year, the strip reads today's price backwards: the yearly sales growth that brings EPS, at the company's own margins, tax and share count, to today's price at the median P/E of the 30 peers in Measuring and Control Equipment (34.5). Low, middle, high opens three columns for one year: the low and high cases take the company's own weaker and stronger years in the table (the lower and upper quarter of its yearly sales growth and operating margin) and the lower and higher of today's P/E and its peers'; the middle is the boxes as they open. Net income keeps the share that went to minority holders; EPS is net income over the diluted shares, on the same basis as the EPS in the table. The price is that year's EPS at the P/E you set, and the yearly return runs from today's price to the year's end. These are your assumptions and your arithmetic, not an estimate of ours. The link carries your columns, so you can send the forecast to someone.| FY2008 | FY2009 † | FY2010 † | FY2011 † | FY2012 † | FY2013 † | FY2014 † | FY2015 † | FY2016 † | FY2017 † | FY2018 | FY2019 † | FY2020 † | FY2021 † | FY2022 | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,660 | 1,551 | 1,704 | 1,921 | 2,105 | 2,158 | 2,070 | 2,105 | 2,116 | 2,257 | 2,778 | 2,884 | 2,663 | 3,828 | 3,312 | 2,751 | 2,755 | 2,856 | 2,912 |
| Cost of revenue | 926 | 852 | 946 | 1,071 | 1,144 | 1,181 | 1,135 | 1,141 | 1,102 | 1,184 | 1,437 | 1,488 | 933 | 1,394 | 1,322 | 1,211 | 1,217 | 1,292 | 1,311 |
| Gross profit | 734 | 699 | 761 | 848 | 962 | 977 | 935 | 964 | 1,013 | 1,073 | 1,341 | 1,396 | 1,730 | 2,434 | 1,990 | 1,540 | 1,538 | 1,564 | 1,601 |
| Gross margin | 44.2% | 45.1% | 44.7% | 44.1% | 45.7% | 45.3% | 45.2% | 45.8% | 47.9% | 47.5% | 48.3% | 48.4% | 65.0% | 63.6% | 60.1% | 56.0% | 55.8% | 54.8% | 55.0% |
| Research and development | 93.0 | 90.5 | 94.8 | 116 | 132 | 132 | 108 | 113 | 124 | 139 | 194 | 189 | 146 | 200 | 222 | 217 | 197 | 216 | 216 |
| Selling, general and administrative | 486 | 477 | 487 | 624 | 627 | 582 | 648 | 587 | 590 | 626 | 812 | 815 | 716 | 975 | 1,026 | 1,023 | 994 | 992 | 1,026 |
| Operating income | 148 | 116 | 158 | 91.1 | 103 | 228 | 165 | 251 | 295 | 296 | 324 | 362 | 867 | 1,258 | 743 | 301 | 347 | 357 | 359 |
| Operating margin | 8.9% | 7.5% | 9.2% | 4.7% | 4.9% | 10.6% | 8.0% | 11.9% | 13.9% | 13.1% | 11.7% | 12.6% | 32.6% | 32.9% | 22.4% | 10.9% | 12.6% | 12.5% | 12.3% |
| Interest expense | n/a | 16.0 | 15.9 | 24.8 | 45.8 | 49.9 | 36.3 | 38.0 | 41.5 | 43.9 | 67.0 | 63.6 | 49.7 | n/a | 104 | 98.8 | 96.3 | 92.2 | 94.0 |
| Pre-tax income | 104 | 100 | 166 | 64.4 | 55.2 | 164 | 124 | 209 | 244 | 297 | 258 | 237 | 800 | 1,204 | 652 | 183 | 316 | 268 | 261 |
| Income tax | 12.7 | 26.7 | 27.0 | 63.2 | -16.1 | -10.6 | -6.3 | 20.0 | 28.4 | 140 | 20.2 | 9.4 | 170 | 314 | 139 | 3.5 | 33.1 | 28.4 | 23.4 |
| Effective tax rate | 12.3% | 26.7% | 16.3% | 98.2% | -29.2% | -6.5% | -5.1% | 9.6% | 11.6% | 47.1% | 7.8% | 4.0% | 21.2% | 26.1% | 21.3% | 1.9% | 10.5% | 10.6% | 9.0% |
| Net income | 126 | 82.1 | 391 | 7.7 | 69.9 | 167 | 158 | 212 | 234 | 293 | 238 | 228 | 728 | 943 | 569 | 693 | 270 | 241 | 238 |
| Net margin | 7.6% | 5.3% | 22.9% | 0.4% | 3.3% | 7.7% | 7.6% | 10.1% | 11.1% | 13.0% | 8.6% | 7.9% | 27.3% | 24.6% | 17.2% | 25.2% | 9.8% | 8.4% | 8.2% |
| Diluted EPS | $1.07 | $0.70 | $3.31 | $0.07 | $0.61 | $1.47 | $1.39 | $1.87 | $2.12 | $2.64 | $2.13 | $2.04 | $6.49 | $8.08 | $4.50 | $5.55 | $2.20 | $2.07 | $2.10 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
From each year's 10-K, linked; TTM is the last four quarters.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.Revenue by segment FY2010 to FY2025
| FY2010 | FY2011 | FY2012 | FY2012 | FY2013 | FY2014 | FY2016 | FY2017 | FY2017 | FY2018 | FY2019 | FY2021 | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 896 | 1,293 | 1,458 | 1,399 | 1,431 | 50.1% |
| Diagnostics | n/a | n/a | n/a | n/a | n/a | 586 | 576 | 603 | 679 | 1,085 | 1,138 | 2,067 | 2,932 | 2,019 | 1,292 | 1,356 | 1,425 | 49.9% |
| Discovery & Analytical Solutions | n/a | n/a | n/a | n/a | n/a | 1,484 | 1,528 | 1,513 | 1,578 | 1,693 | 1,746 | 596 | n/a | n/a | n/a | n/a | n/a | n/a |
| Environmental Health | 819 | 908 | 941 | 941 | 832 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Human Health | 732 | 794 | 978 | 1,165 | 1,326 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Life Sciences FY2022 to FY2025Diagnostics FY2014 to FY2025Discovery & Analytical Solutions FY2014 to FY2021Human Health FY2010 to FY2013Environmental Health FY2010 to FY2013
$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.Profit by segment FY2010 to FY2025, 1 year left out
The operating profit each segment reports. Costs Revvity does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.
| FY2010 | FY2011 | FY2012 | FY2012 | FY2013 | FY2014 | FY2016 | FY2017 | FY2017 | FY2018 | FY2019 | FY2021 | FY2023 | FY2023 | FY2024 | FY2025 | Margin FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 503 | 512 | 467 | 458 | 32.0% |
| Diagnostics | n/a | n/a | n/a | n/a | n/a | 125 | 146 | 148 | 147 | 153 | 189 | 874 | 781 | 298 | 354 | 344 | 24.2% |
| Discovery & Analytical Solutions | n/a | n/a | n/a | n/a | n/a | 162 | 163 | 197 | 205 | 230 | 238 | 183 | n/a | n/a | n/a | n/a | n/a |
| Environmental Health | 76.4 | 95.1 | 109 | 112 | 84.7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Human Health | 80.2 | 97.9 | 89.7 | 63.8 | 169 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Life Sciences FY2023 to FY2025Discovery & Analytical Solutions FY2014 to FY2021Human Health FY2010 to FY2013Diagnostics FY2014 to FY2025Environmental Health FY2010 to FY2013
$ million; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.
FY2025Share of salesShare of profit
Life Sciences50%57%
Diagnostics50%43%
Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.Revenue by product or service FY2017 to FY2025
| FY2017 | FY2017 | FY2018 | FY2019 | FY2021 | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | 1,397 | 1,477 | 1,935 | 2,017 | 2,281 | 2,735 | 2,635 | 2,416 | 2,338 | 2,390 | 83.7% |
| Service | 719 | 780 | 843 | 867 | 382 | 1,093 | 677 | 335 | 417 | 466 | 16.3% |
ProductService
$ million; hover a block for its figure and share
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.Revenue by region FY2010 to FY2025
| FY2010 | FY2011 | FY2012 | FY2012 | FY2013 | FY2014 | FY2016 | FY2017 | FY2017 | FY2018 | FY2019 | FY2021 | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1,065 | 1,119 | 1,037 | 1,807 | 1,663 | 1,216 | 1,223 | 1,256 | 44.0% |
| Europe | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 778 | 787 | 1,022 | 1,217 | 832 | 747 | 743 | 825 | 28.9% |
| Asia | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 935 | 977 | 604 | 804 | 817 | 788 | 789 | 775 | 27.1% |
| China | 104 | 132 | 164 | 216 | 255 | 258 | 297 | 337 | 375 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| France | 76.5 | 82.3 | 85.4 | 84.4 | 81.7 | 77.6 | 70.7 | 71.1 | 80.2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Germany | 95.4 | 91.7 | 113 | 106 | 99.2 | 88.1 | 86.6 | 89.8 | 91.7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| India | n/a | n/a | n/a | n/a | n/a | n/a | 40.2 | 43.9 | 84.8 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Italy | 68.9 | 67.4 | 74.9 | 69.6 | 78.1 | 80.8 | 71.2 | 70.9 | 77.5 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Japan | 68.9 | 75.7 | 90.0 | 114 | 95.7 | 90.3 | 69.4 | 66.0 | 76.3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other International | 436 | 489 | 563 | 583 | 587 | 600 | 546 | 529 | 569 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United Kingdom | 104 | 97.2 | 102 | 119 | 134 | 81.1 | 69.1 | 65.9 | 65.2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States | 596 | 670 | 729 | 813 | 827 | 795 | 854 | 842 | 837 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Americas FY2018 to FY2025Europe FY2018 to FY2025Asia FY2018 to FY2025United States FY2010 to FY2017Other International FY2010 to FY2017China FY2010 to FY2017Germany FY2010 to FY2017United Kingdom FY2010 to FY2017Japan FY2010 to FY2017France FY2010 to FY2017Other
$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.First forecast against the result
Revvity's adjusted EPS landed at or above the top of the range in 6 of the 6 years shown (FY2017 to FY2025).
- At or above the top of the range
- Inside the range
- Under the range
Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.
| Fiscal year | First forecast adjusted EPS | Result |
|---|---|---|
| FY2017 | $2.75 to $2.85 | $2.90 |
| FY2019 | $4.00 to $4.05 | $4.10 |
| FY2020 | $4.50 to $4.60 | $8.30 |
| FY2022 | $6.80 to $7.00 | $7.95 |
| FY2024 | $4.55 to $4.75 | $4.90 |
| FY2025 | $4.90 to $5.00 | $5.06 |
- FY2026 forecast
- Adjusted EPS $5.35 to $5.45, given 2 February 2026. Its result comes with the fourth-quarter results for FY2026.
- First forecast
- The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
- Result
- The figure the company reported for that year with its next fourth-quarter results.
- Adjusted EPS
- The company's own measure, which leaves out items it names, so it differs from the EPS in the tables above.
- Years left out
- Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.
Cash flow
Follow the cash: free cash flow, which is operating cash flow less capital expenditure and share-based pay, for five years and after, in today's money.
Read more
The figure a share at the top is what a discounted cash flow calls intrinsic value, worked out on your assumptions. Everything after year five is one sum: the sixth year's cash, growing at the long-run rate every year after, added up and brought back to today's money. Each year runs from the last twelve months as filed. Sales growth opens where Play it forward does: the company's own five-year rate, easing a third of the way each year toward the median of the 42 peers in Measuring and Control Equipment (9.4% a year); change a year and the years after it follow. Operating cash flow, capital expenditure and share-based pay open at the company's own median share of sales over its last five years, shown under each row. Share-based pay is taken off because operating cash flow adds back the shares paid to staff as if they cost nothing; set it to 0 to leave it in. Capital spending counts every capital line the company files in its cash flow, such as equipment it leases to customers, software, wells or property it develops, named under the row, while the Capital expenditure row in the table below stays the one line as filed; buying a business, securities or a finished property is not counted. The discount rate opens at 10%, about what US stocks have returned a year over the long run, so it is the return you give up by holding this company instead of the market; the growth after year five opens at 3%, a little under the US economy's long-run growth in dollars, because no company outgrows it for ever. Net debt is the debt and short-term borrowings less the cash on the latest balance sheet that shows the debt; the figure per share divides what is left by the diluted share count. These are your assumptions and your arithmetic, not an estimate of ours. The link carries them, so you can send them to someone.| FY2008 | FY2009 † | FY2010 † | FY2011 † | FY2012 † | FY2013 † | FY2014 † | FY2015 † | FY2016 † | FY2017 † | FY2018 | FY2019 † | FY2020 † | FY2021 † | FY2022 | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 218 | 149 | 164 | 225 | 152 | 159 | 282 | 287 | 351 | 288 | 311 | 363 | 892 | 1,411 | 680 | 91.3 | 628 | 583 | 628 |
| Capital expenditure | 35.3 | 25.5 | 33.6 | 30.6 | 42.4 | 39.0 | 27.2 | 28.2 | 31.7 | 39.1 | 93.3 | 76.3 | 63.6 | 86.0 | 85.6 | 81.4 | 86.6 | 73.5 | 69.5 |
| Free cash flow | 183 | 123 | 131 | 194 | 110 | 120 | 254 | 259 | 319 | 249 | 218 | 287 | 829 | 1,325 | 594 | 9.9 | 542 | 509 | 558 |
| Free cash flow margin | 11.0% | 7.9% | 7.7% | 10.1% | 5.2% | 5.5% | 12.3% | 12.3% | 15.1% | 11.0% | 7.8% | 10.0% | 31.1% | 34.6% | 17.9% | 0.4% | 19.7% | 17.8% | 19.2% |
| Cash from investing | -136 | -154 | 295 | -910 | -80.3 | -1.2 | -296 | -101 | -83.9 | -1,267 | -160 | -488 | -504 | -4,113 | -133 | 1,314 | 776 | -17.4 | -83.3 |
| Cash from financing | -101 | 2.4 | -218 | 397 | -44.2 | -154 | 30.9 | -107 | -115 | 782 | -179 | -150 | -203 | 2,942 | -662 | -947 | -1,128 | -858 | -503 |
| Depreciation and amortisation | 77.4 | 80.8 | 89.2 | 111 | 125 | 127 | 110 | 105 | 100.0 | 105 | 181 | 214 | 202 | 311 | 427 | 432 | 428 | 405 | 412 |
| Share-based compensation | 18.1 | 14.0 | 12.4 | 15.5 | 20.6 | 14.1 | 14.1 | 17.3 | 17.2 | 25.4 | 28.8 | 31.5 | 26.9 | 29.7 | 51.5 | 41.4 | 37.8 | 22.8 | n/a |
| Buybacks | 75.5 | 14.6 | 72.8 | 110 | 2.1 | 127 | 65.5 | 76.4 | 152 | 3.8 | 57.4 | 6.3 | 6.9 | 73.1 | 80.6 | 389 | 370 | 821 | 476 |
| Dividends paid | 33.1 | 32.7 | 33.0 | 31.8 | 31.9 | 31.6 | 31.6 | 31.6 | 30.8 | 30.8 | 31.0 | 31.1 | 31.2 | 32.4 | 35.3 | 35.0 | 34.5 | 32.8 | 31.7 |
| Dividend per share | n/a | n/a | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | n/a | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 |
| Diluted shares, weighted | n/a | 117m | 118m | 114m | 115m | 114m | 114m | 113m | 110m | 111m | 112m | 112m | 112m | 117m | 126m | 125m | 123m | 117m | 112m |
| Shares outstanding at period end | n/a | 117m | 116m | 113m | 115m | 113m | 112m | 112m | 112m | 110m | 111m | 111m | 112m | 126m | 126m | 123m | 121m | 112m | 112m |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Cash paid in the year, from the cash flow statement.
Read more
The dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.Balance sheet
| FY2008 | FY2009 † | FY2010 † | FY2011 † | FY2012 † | FY2013 † | FY2014 † | FY2015 † | FY2016 † | FY2017 † | FY2018 | FY2019 † | FY2020 † | FY2021 † | FY2022 | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Funded by | |||||||||||||||||||
| Shareholders' equity | 1,568 | 1,629 | 1,926 | 1,842 | 1,940 | 1,994 | 2,042 | 2,110 | 2,154 | 2,503 | 2,585 | 2,814 | 3,735 | 7,141 | 7,383 | 7,873 | 7,667 | 7,250 | 7,229 |
| Debt | n/a | 558 | 426 | 948 | 941 | 935 | 1,053 | 1,013 | 1,046 | 2,006 | 1,891 | 2,074 | 2,009 | 5,027 | 4,429 | 3,927 | 3,172 | 3,239 | 3,222 |
| Operating lease liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.0 | 146 | 188 | 147 | 170 | 133 | 152 | 148 | 136 |
| Other liabilities | n/a | 872 | 857 | 1,065 | 1,021 | 1,017 | 1,039 | 1,043 | 1,077 | 1,582 | 1,499 | 1,504 | 2,027 | 2,685 | 2,148 | 1,632 | 1,402 | 1,530 | 1,459 |
| Total liabilities and equity | n/a | 3,059 | 3,209 | 3,856 | 3,902 | 3,947 | 4,134 | 4,166 | 4,277 | 6,091 | 5,976 | 6,539 | 7,960 | 15,001 | 14,130 | 13,565 | 12,392 | 12,168 | 12,046 |
| Owned | |||||||||||||||||||
| Fixed assets | n/a | 153 | 162 | 175 | 211 | 183 | 176 | 138 | 145 | 298 | 319 | 318 | 368 | 486 | 483 | 510 | 482 | 479 | 456 |
| Goodwill | n/a | 1,419 | 1,505 | 2,094 | 2,123 | 2,143 | 2,244 | 2,237 | 2,248 | 3,002 | 2,953 | 3,111 | 2,640 | 6,627 | 6,482 | 6,534 | 6,464 | 6,613 | 6,608 |
| Intangible assets | n/a | 443 | 424 | 662 | 530 | 460 | 490 | 486 | 420 | 1,347 | 1,200 | 1,283 | 1,366 | 3,822 | 3,377 | 3,022 | 2,641 | 2,347 | 2,224 |
| Investments | n/a | 2.3 | 1.4 | 1.1 | 1.1 | 1.3 | 1.6 | 1.6 | 1.7 | 2.2 | 2.4 | 2.9 | 2.2 | 33.7 | 11.1 | 704 | 27.4 | 28.0 | n/a |
| Cash and equivalents | 179 | 180 | 420 | 142 | 173 | 175 | 175 | 238 | 359 | 202 | 163 | 192 | 387 | 603 | 454 | 913 | 1,163 | 920 | 1,023 |
| Receivables | n/a | 320 | 357 | 410 | 457 | 467 | 471 | 415 | 426 | 552 | 633 | 725 | 1,155 | 708 | 613 | 633 | 632 | 745 | 709 |
| Inventory | n/a | 179 | 207 | 241 | 248 | 261 | 285 | 259 | 247 | 352 | 338 | 357 | 515 | 426 | 405 | 428 | 368 | 379 | 379 |
| Other assets | n/a | 363 | 133 | 132 | 159 | 256 | 291 | 392 | 430 | 336 | 368 | 549 | 1,528 | 2,295 | 2,304 | 821 | 615 | 657 | 647 |
| Total assets | n/a | 3,059 | 3,209 | 3,856 | 3,902 | 3,947 | 4,134 | 4,166 | 4,277 | 6,091 | 5,976 | 6,539 | 7,960 | 15,001 | 14,130 | 13,565 | 12,392 | 12,168 | 12,046 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
At the fiscal year end; the TTM column is the latest quarter end.
Read more
Both totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.Compounded growth
| 10 years | 5 years | 3 years | TTM | |
|---|---|---|---|---|
| Sales growth, compounded | 3.1% | 1.4% | -4.8% | 4.1% |
| Profit growth, compounded | 1.3% | -19.8% | -24.9% | -16.7% |
| Return on equity, average | 9.6% | 7.3% | 5.2% | 3.3% |
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read more
Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.Questions
What was Revvity's revenue in fiscal 2025?
Revvity (RVTY) reported revenue of $2.9 billion for fiscal 2025, the year ended 28 December 2025, up 3.7% on the year before.
How much did Revvity earn in fiscal 2025?
Net income was $241 million for fiscal 2025, and diluted earnings per share $2.07.
What is Revvity's P/E ratio?
At the close of 6 November 2026, Revvity traded at 73.9 times its earnings over the twelve months to 5 July 2026.
What is Revvity's market cap?
The market cap of Revvity was $17.3 billion at the close of 6 November 2026.
Does Revvity pay a dividend?
Yes. Revvity declared $0.28 a share in dividends over the four quarters to 5 July 2026.
Peers: Measuring and Control Equipment
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Agilent Technologies, Inc. A | $49.3 billion | 34.40 | 19.6% | 22.2% | 8.6% | 0.54 | 0.6% |
| Waters Corp. WAT | $45.0 billion | 114.14 | 1.1% | 7.1% | 52.5% | 0.33 | n/a |
| Mettler Toledo International Inc. MTD | $37.3 billion | 37.30 | 1,202.8% | n/a | 6.5% | 26.06 | n/a |
| Illumina, Inc. ILMN | $32.2 billion | 36.67 | 28.5% | 21.2% | 5.8% | 0.57 | n/a |
| Revvity, Inc. RVTY | $17.3 billion | 73.89 | 3.3% | 12.3% | 4.1% | 0.45 | 0.2% |
| Avantor, Inc. AVTR | $10.5 billion | 30.93 | 5.8% | 7.3% | 0.9% | 0.63 | n/a |
| Bio-Rad Laboratories, Inc. BIO | $10.3 billion | 10.06 | 13.5% | -2.4% | 1.4% | 0.16 | n/a |
| Bruker Corp. BRKR | $9.4 billion | n/a | -5.4% | -2.0% | 2.2% | 0.74 | n/a |
| 10x Genomics, Inc. TXG | $7.8 billion | n/a | -8.0% | -11.7% | -3.6% | 0.00 | n/a |
| Alamar Biosciences, Inc. ALMR | $1.9 billion | n/a | -18.1% | -42.1% | n/a | 0.00 | n/a |
| Cytek Biosciences, Inc. CTKB | $765 million | n/a | -25.3% | -21.1% | 5.5% | 0.00 | n/a |
| Pacific Biosciences of California, Inc. PACB | $703 million | n/a | n/a | -81.3% | 4.4% | n/a | 0.0% |
All 49 in Measuring and Control Equipment
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. TMO | $257.5 billion | 36.65 | 12.9% | 17.9% | 8.3% | 0.76 | 0.3% |
| KLA Corp. KLAC | $180.5 billion | 34.62 | 80.6% | n/a | 15.8% | 0.88 | 0.6% |
| Danaher Corp. DHR | $162.0 billion | 37.69 | 8.1% | 20.4% | 5.5% | 0.49 | 0.6% |
| Trane Technologies plc TT | $88.0 billion | 28.38 | 34.6% | 17.9% | 10.3% | 0.46 | 1.0% |
| AMETEK Inc. AME | $52.4 billion | 32.25 | 13.9% | 26.0% | 14.3% | 0.57 | 0.6% |
| Agilent Technologies, Inc. A | $49.3 billion | 34.40 | 19.6% | 22.2% | 8.6% | 0.54 | 0.6% |
| Roper Technologies Inc. ROP | $47.2 billion | 18.81 | 13.5% | 28.0% | 9.2% | 0.51 | 0.8% |
| Keysight Technologies, Inc. KEYS | $46.3 billion | 37.33 | 19.2% | 20.3% | 25.5% | 0.38 | n/a |
| Waters Corp. WAT | $45.0 billion | 114.14 | 1.1% | 7.1% | 52.5% | 0.33 | n/a |
| Rockwell Automation, Inc. ROK | $41.7 billion | 35.21 | 34.4% | 22.7% | 11.3% | 0.93 | 1.5% |
| Coherent Corp. COHR | $38.0 billion | 40.01 | 8.5% | 12.5% | 30.8% | 0.35 | n/a |
| Mettler Toledo International Inc. MTD | $37.3 billion | 37.30 | 1,202.8% | n/a | 6.5% | 26.06 | n/a |
| Teradyne, Inc. TER | $34.1 billion | 25.05 | 37.2% | 32.1% | 74.9% | 0.00 | 0.2% |
| Illumina, Inc. ILMN | $32.2 billion | 36.67 | 28.5% | 21.2% | 5.8% | 0.57 | n/a |
| Veralto Corp. VLTO | $28.5 billion | 28.98 | 31.0% | 21.8% | 6.4% | 0.90 | 0.4% |
| Fortive Corp. FTV | $19.5 billion | 31.14 | 11.0% | 19.6% | 7.0% | 0.59 | 0.4% |
| Revvity, Inc. RVTY | $17.3 billion | 73.89 | 3.3% | 12.3% | 4.1% | 0.45 | 0.2% |
| MKS Inc. MKSI | $13.0 billion | 22.80 | 18.3% | 18.2% | 24.6% | 1.15 | 0.5% |
| Trimble Inc. TRMB | $12.4 billion | n/a | -3.2% | 16.5% | 6.9% | 0.31 | n/a |
| Avantor, Inc. AVTR | $10.5 billion | 30.93 | 5.8% | 7.3% | 0.9% | 0.63 | n/a |
| Bio-Rad Laboratories, Inc. BIO | $10.3 billion | 10.06 | 13.5% | -2.4% | 1.4% | 0.16 | n/a |
| Bruker Corp. BRKR | $9.4 billion | n/a | -5.4% | -2.0% | 2.2% | 0.74 | n/a |
| Onto Innovation Inc. ONTO | $8.5 billion | 65.10 | 6.9% | 12.0% | 8.1% | 0.00 | n/a |
| Cognex Corp. CGNX | $8.0 billion | 33.37 | 14.1% | 25.0% | 15.8% | 0.00 | 0.7% |
| 10x Genomics, Inc. TXG | $7.8 billion | n/a | -8.0% | -11.7% | -3.6% | 0.00 | n/a |
| Ralliant Corp. RAL | $7.5 billion | n/a | -73.4% | -48.3% | n/a | 0.71 | 0.3% |
| Sensata Technologies Holding plc ST | $5.7 billion | 15.72 | 12.0% | 15.1% | 4.1% | 0.78 | 1.2% |
| Vontier Corp. VNT | $5.7 billion | 17.30 | 28.4% | 19.4% | 0.3% | 1.57 | 0.2% |
| Badger Meter Inc. BMI | $4.5 billion | 36.47 | 19.4% | 18.8% | -2.2% | 0.00 | 1.0% |
| Mirion Technologies, Inc. MIR | $4.4 billion | 149.58 | 1.6% | 6.0% | 19.6% | 0.67 | n/a |
| Itron, Inc. ITRI | $4.3 billion | 15.90 | 16.5% | 13.7% | -3.6% | 0.95 | n/a |
| Alamar Biosciences, Inc. ALMR | $1.9 billion | n/a | -18.1% | -42.1% | n/a | 0.00 | n/a |
| Cohu Inc. COHU | $1.9 billion | n/a | -2.9% | -2.4% | 34.0% | 0.38 | n/a |
| Aehr Test Systems AEHR | $1.7 billion | 1,338.88 | 1.0% | -5.6% | 26.8% | 0.00 | n/a |
| Allient Inc. ALNT | $1.4 billion | 36.68 | 11.4% | 9.8% | 12.6% | 0.53 | 0.2% |
| Transcat Inc. TRNS | $953 million | n/a | n/a | n/a | n/a | 0.38 | n/a |
| Cytek Biosciences, Inc. CTKB | $765 million | n/a | -25.3% | -21.1% | 5.5% | 0.00 | n/a |
| Mesa Laboratories Inc. MLAB | $718 million | 152.76 | 2.5% | 9.0% | 3.0% | 0.76 | 0.5% |
| Pacific Biosciences of California, Inc. PACB | $703 million | n/a | n/a | -81.3% | 4.4% | n/a | 0.0% |
| Frequency Electronics Inc. FEIM | $661 million | 241.04 | 2.2% | 2.5% | 6.3% | 0.00 | n/a |
| Senseonics Holdings, Inc. SENS | $454 million | n/a | -121.1% | -223.2% | 90.6% | 0.62 | n/a |
| 908 Devices Inc. MASS | $402 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Quantum-Si Inc. QSI | $291 million | n/a | -53.1% | -7,474.5% | -60.2% | 0.00 | n/a |
| Nautilus Biotechnology, Inc. NAUT | $284 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Intest Corp. INTT | $173 million | 38.59 | 3.4% | 3.3% | 16.6% | 0.05 | n/a |
| Hurco Companies Inc. HURC | $132 million | n/a | -3.4% | -2.8% | -1.9% | n/a | n/a |
| Kewaunee Scientific Corp. KEQU | $97 million | 12.14 | 11.0% | 5.4% | 5.3% | 0.25 | n/a |
| Seer, Inc. SEER | $90 million | n/a | -30.1% | -498.2% | -12.7% | 0.00 | 0.0% |
| Rapid Micro Biosystems, Inc. RPID | $32 million | n/a | -288.5% | -141.5% | 16.1% | 1.08 | n/a |
15 companies share its SEC industry code (Laboratory Analytical Instruments); the rest are the names nearest in size in its wider industry, Measuring and Control Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read more
By market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.The public record on RVTY
| Dividends | $0.28 a share over the four quarters to 5 July 2026, a 0.18% yield |
| Filings | 16 in twelve months: 6 current reports (8-K), about 5 results of operations; 3 other events; 1 charter or bylaw amendment, or fiscal year change; 1 shareholder vote; 1 regulation FD disclosure |
| Planned insider sales | 10 Form 144 notices in twelve months, $6.0 million; latest 1 October 2026 |
| Options tape | put/call 0.92 by open interest at the 6 November 2026 close; the straddle prices a 9.0% move to 20 November 2026 |
| 13F holders | 547 funds reported a position for the quarter to 30 June 2026; largest T. Rowe Price Investment Management, Inc. |
| Insider trading | 17 sales and 0 purchases on Form 4 in twelve months |
| Congress | 4 House trades disclosed in six months |
| Short interest | 6.4 million shares short, 3.56 days to cover at 15 October 2026 |
| Documents | the 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked |
Filings
| Filing | Period | Filed | Where |
|---|---|---|---|
| 10-Q | 5 July 2026 | 11 August 2026 | EDGAR |
| 10-Q | 5 April 2026 | 12 May 2026 | EDGAR |
| 10-K | 28 December 2025 | 24 February 2026 | EDGAR |
| 10-Q | 28 September 2025 | 4 November 2025 | EDGAR |
| 10-Q | 29 June 2025 | 5 August 2025 | EDGAR |
| 10-Q | 30 March 2025 | 6 May 2025 | EDGAR |
| 10-K | 29 December 2024 | 25 February 2025 | EDGAR |
| 10-Q | 29 September 2024 | 6 November 2024 | EDGAR |
| 10-Q | 30 June 2024 | 6 August 2024 | EDGAR |
| 10-Q | 31 March 2024 | 7 May 2024 | EDGAR |
Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.